WebMay 9, 2016 · Dicerna Pharmaceuticals, Inc., is an RNA interference-based biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver, for other therapeutic areas in which the liver plays a key role, and for cancers that are genetically defined. WebLegal Name Dicerna Pharmaceuticals, Inc. Stock Symbol NASDAQ:DRNA. Company Type For Profit. Contact Email [email protected]. Phone Number 6176126254. Dicerna …
stock3: Die Homebase für Ihren Börsenalltag stock3
WebOct 29, 2024 · October 29, 2024. Eli Lilly will apply Dicerna Pharmaceuticals’ GalXC™ RNA interference (RNAi) technology platform to discover, develop, and commercialize new treatments based on more than 10 ... WebDicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company … phonemes used in reading instruction
Dicerna Pharmaceuticals Inc (DRNA) Quote - Investors Hub
WebDec 27, 2024 · Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing medicines that are … DICERNA PHARMACEUTICALS INC : Completion of Acquisition or … WebAug 6, 2024 · In the last 3 months, 7 analysts have offered 12-month price targets for Dicerna Pharmaceuticals. The company has an average price target of $39.0 with a high of $48.00 and a low of $30.00. WebApr 3, 2024 · Dicerna Pharmaceuticals (NASDAQ:DRNA) has a market capitalization of $2.99 billion and generates $164.31 million in revenue each year. The biopharmaceutical company earns $-112,750,000.00 in net … how do you spell tattered